Skip to main content
Explore URMC
menu

Lisa A. Beck, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-7546

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Research Labs

Faculty Appointments

Patient Care Setting

Dermatology

Biography

Dr. Beck brings more than 20 years' experience to the treatment of atopic dermatitis and eczema. She is currently involved in an NIH-funded study to determine why certain patients are susceptible to the herpes simplex and Staphylococcus aureus viruses. Dr. Beck received her undergraduate degree from Mount Holyoke College and her medical degree from the State University of New York at Stony Brook.

Research

Dr. Lisa Beck has dedicated her 25 year career to finding safe, effective treatments for patients with atopic dermatitis, more commonly known as eczema. Internationally recognized as an eczema expert, her research was instrumental in the development of the first biologic drug called dupilumab (brand name Dupixent) for the treatment of adults with moderate to severe eczema. She was the lead author of a 2014 New England Journal of Medicine paper that set the stage for the FDA approval of this drug in March 2017. She is Co-Director of the URMC Center for Allergic Disease Research (CADR) which was recently chosen as one of four US centers with the World Allergy Organizations Center of Excellence designation. She has been the secretary of the International Eczema Council (IEC) since its inception in 2014, emeritus member of the National Eczema Association (NEA) Scientific Advisory committee, and President-Elect of the Society of Investigative Dermatology. She has been NIH-funded to study this disease since 1992 and her main focus is now on understanding why certain eczema patients are susceptible to cutaneous viral infections such as herpes simplex as well as bacterial colonization or infection with Staphylococcus aureus. As the founding director of the URMC Dermatology Clinical Trials Unit, she has completed >14 clinical AD registry, mechanistic, and interventional trials, all of which met or exceeded enrollment/retention expectations and has > 500 person URMC AD patient Registry. She has had continuous NIH funding since 1994, and has been co-PI of the NIH/NIAID-funded Atopic Dermatitis Research Network (ADRN) since it inception in 2004, which has amassed the largest cross-sectional registry of deeply phenotyped AD subjects in the world. She has been PI of the ADRN Biomarker Repository since 2014 with >150,000 serum and skin swab samples. Dr. Beck received her undergraduate degree from Mount Holyoke College, her medical degree from the State University of New York at Stony Brook, two years of internal medicine training at Strong Memorial Hospital, Dermatology residency at Duke University and an Immunology Research fellowship at Johns Hopkins University.

Credentials

Education

1985
MD | Stony Brook University Hospital (USA)

Post-doctoral Training & Residency

07/01/1987 - 07/31/1990
Residency in Dermatology at Duke University Eye Center

07/01/1986 - 07/31/1987
Residency in Internal Medicine at University of Rochester Medical Center

06/27/1985 - 07/31/1986
Internship in Internal Medicine at University of Rochester Medical Center

VIEW ALL expand_more

Awards

2008
Dermatology Faculty Teaching Award
Sponsor: University of Rochester Medical Center

2007
Mentor for NEASE Skin Research Grant Recipient
Sponsor: NEASE

2007
Mentor for AAAAI Summer Research Grant Recipient
Sponsor: AAAAI

2006
Mentor for Astellas Skin Research Grant Recipient
Sponsor: Astellas

2005
Mentor for Fujisawa AAAAI Research Grant Recipient
Sponsor: Fujisawa

1997
Mentor for Howard Hughes Summer Fellowship Recipient
Sponsor: Howard Hughes

1994
Physician-Scientist Award
Sponsor: National Institute of Health

1994
Research Award
Sponsor: Dermatology Foundation

1992
Teaching Appreciation Award
Sponsor: Johns Hopkins University
Location: Dermatology Department

1992
Internal Medicine Teaching Award
Sponsor: Francis Scott Key Medical Center

VIEW ALL expand_more

Patents

Patent Title: System and Method for Studying Epidermis Samples Ex Vivo
Patent #: 8,993,257
Issue Date: Mar 31, 2015
Country: United States
Invented By: Lisa A Beck, Anna De Benedetto

Patent Title: Designed Peptides for Tight Junction Barrier Modulation
Patent #: 3033108
Issue Date: Mar 24, 2021
Country: Europe
Invented By: Elizabeth A Anderson, Lisa A Beck, Anna De Benedetto, Benjamin Locke Miller

Patent Title: Designed Peptides for Tight Junction Barrier Modulation
Patent #: FR3033108
Issue Date: Mar 24, 2021
Country: France
Invented By: Elizabeth A Anderson, Lisa A Beck, Anna De Benedetto, Benjamin Locke Miller

Patent Title: Designed Peptides for Tight Junction Barrier Modulation
Patent #: DE3033108
Issue Date: Mar 24, 2021
Country: Germany
Invented By: Elizabeth A Anderson, Lisa A Beck, Anna De Benedetto, Benjamin Locke Miller

Patent Title: Designed Peptides for Tight Junction Barrier Modulation
Patent #: IT3033108
Issue Date: Mar 24, 2021
Country: Italy
Invented By: Elizabeth A Anderson, Lisa A Beck, Anna De Benedetto, Benjamin Locke Miller

Patent Title: Designed Peptides for Tight Junction Barrier Modulation
Patent #: ES3033108
Issue Date: Mar 24, 2021
Country: Spain
Invented By: Elizabeth A Anderson, Lisa A Beck, Anna De Benedetto, Benjamin Locke Miller

Patent Title: Designed Peptides for Tight Junction Barrier Modulation
Patent #: GB3033108
Issue Date: Mar 24, 2021
Country: United Kingdom
Invented By: Elizabeth A Anderson, Lisa A Beck, Anna De Benedetto, Benjamin Locke Miller

Patent Title: Designed Peptides for Tight Junction Barrier Modulation
Patent #: ZL 201480052086.0
Issue Date: Jun 02, 2020
Country: China, People's Republic of
Invented By: Elizabeth A Anderson, Lisa A Beck, Anna De Benedetto, Benjamin Locke Miller

Patent Title: Designed Peptides for Tight Junction Barrier Modulation
Patent #: 9,757,428
Issue Date: Sep 12, 2017
Country: United States
Invented By: Elizabeth A Anderson, Lisa A Beck, Anna De Benedetto, Benjamin Locke Miller

VIEW ALL expand_more

Publications

Journal Articles

2/2023
Pope EM, Laageide L, Beck LA. "Management of Allergic Skin Disorders in Pregnancy." Immunology and allergy clinics of North America.. 2023 Feb; 43(1):117-132. Epub 2022 Oct 28.

12/3/2022
Beck LA, Bieber T, Weidinger S, Tauber M, Saeki H, Irvine AD, Eichenfield LF, Werfel T, Arlert P, Jiang L, Røpke M, Paller AS. "Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial." Journal of the American Academy of Dermatology.. 2022 Dec 3; Epub 2022 Dec 03.

9/2022
Beck LA, Cork MJ, Amagai M, De Benedetto A, Kabashima K, Hamilton JD, Rossi AB. "Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis." JID innovations : skin science from molecules to population health.. 2022 Sep; 2(5):100131. Epub 2022 Apr 26.

Books & Chapters

2008
Chapter Title: Update on the Managment of Atopic Dermatitis
Book Title: Allergy Frontiers: Epigenetics to Future Perspectives
Author List: Ibrahim SF, DeBenedetto A, Beck LA
Edited By: Pawankar R, Holgate S, Rosenwasser L
Published By: Springer 2008 in Tokyo, Japan

2007
Chapter Title: Regulation of the Production and Activation of Eosinophils and Neutrophils
Book Title: Dermatology in General Medicine
Author List: Beck LA, Loveless J, Holland S
Edited By: Freedberg I, Katz S, Wolff K, Eisen A, Austen KF and Goldsmith L
Published By: McGraw-Hill Co. 2007 in New York

2004
Chapter Title: Regulation of the Production and Activation of Eosinophils
Book Title: Dermatology In General Medicine
Author List: Rencic A, Beck LA
Edited By: Freedburg I, Eisen A, Wolff K, Austen KF, Goldsmith L, and Katz SI
Published By: Mc-Graw-Hill Co. 2004 in New York

VIEW ALL PUBLICATIONS